Iovance Biotherapeutics ( IOVA 2.52% ), a biotechnology company specializing in cell therapies for solid tumors, reported GAAP earnings on August 7, 2025. The standout news was a 93% year-over-year GAAP revenue growth compared to Q2 2024, driven by its Amtagvi T cell therapy, but both GAAP revenue and earnings fell short of Wall Street expectations. Revenue (GAAP) reached $60.0 million compared to the $67.1 million consensus, while the loss per share of $0.33 (GAAP) was deeper than the projected $0.28 loss. Higher costs, particularly in manufacturing and research and development, contributed to a larger net loss. Despite the revenue miss on a GAAP basis, the company demonstrated ongoing uptake for its core product and maintained its full-year financial guidance, reflecting steady operational progress in a pivotal launch year.